SpaceX aims to file a prospectus for an initial public offering as soon as this week, the Information reported , kicking off one of the year’s most-anticipated market debuts. Elon Musk ’s company could try to raise more than $75 billion, the media outlet said, citing a person with direct knowledge of the plans. It had been expected to raise as much as $50 billion in a record-setting IPO this summe...
SpaceX aims to file a prospectus for an initial public offering as soon as this week, the Information reported , kicking off one of the year’s most-anticipated market debuts. Elon Musk ’s company could try to raise more than $75 billion, the media outlet said, citing a person with direct knowledge of the plans. It had been expected to raise as much as $50 billion in a record-setting IPO this summer that could value the space exploration company at more than $1.75 trillion. That capital-raising would shatter the previous high watermark set by Saudi Aramco ’s $29.4 billion listing in 2019. Read More: SpaceX Blockbuster IPO Lures Investors Into Murky Private Deals
Earnings Call Insights: BioCardia (BCDA) Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented as a late-breaking clinical trial. He emphasized, "The key takeaway from these new results is in this title. The Cardiac HF echocardiography clinical results......
Earnings Call Insights: BioCardia (BCDA) Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented as a late-breaking clinical trial. He emphasized, "The key takeaway from these new results is in this title. The Cardiac HF echocardiography clinical results... show reductions in left ventricular volume disease when the heart ventricle is fully dilated with a p-value of 0.06 and when the heart is fully contracted with a p-value of 0.09." For the prespecified subgroups of patients with elevated biomarkers of heart stress, he noted differences were clinically meaningful and statistically significant. Altman stated, "We expect to soon submit the Q-sub request on approvability of the CardiAMP system to FDA Center for Biologics Evaluation and Research, or CBER, based on the safety and compelling signals of patients benefits with elevated biomarkers of heart stress from our 3 clinical trials." He also outlined four catalysts for the next quarter: the FDA CardiAMP Heart Failure Q-submission, a formal clinical consultation with Japan PMDA, an FDA feedback meeting on the Helix system, and an abstract presentation at EuroPCR in May. David McClung, CFO, stated, "Total expense accretes approximately 3% year-over-year to $8.3 million in 2025 and compared to $8.1 million in 2024. The primary driver of this change, research and development expense, increased to $5 million in 2025 compared to $4.4 million in 2024." McClung added, "Net loss increased modestly to $8.2 million in 2025 from $7.9 million in 2024. Net cash used in operations was approximately $7.5 million during the year into 2025. That's down from $7.9 million in 2024. The company ended the year with cash and cash equivalents totaling $2.5 million, very comparable to the $2.4 million as of December 31, 2024." Outlook Management expects to "soon submit the Q-sub request on approvabili...
There's a lot in Meta Platforms ' (NASDAQ: META) recent financial updates for the bulls to like. The social media giant is generating incredible top-line momentum. In addition, management guided for even faster growth in Q1. But here's the issue: Meta's artificial intelligence (AI) growth initiatives are slowing its earnings growth. And it seems to be worrying investors. The stock is down about 10...
There's a lot in Meta Platforms ' (NASDAQ: META) recent financial updates for the bulls to like. The social media giant is generating incredible top-line momentum. In addition, management guided for even faster growth in Q1. But here's the issue: Meta's artificial intelligence (AI) growth initiatives are slowing its earnings growth. And it seems to be worrying investors. The stock is down about 10% year to date. Could the stock go even lower this year? Given the staggering shift in the company's cost structure, possibly. Here is a closer look at why the stock's recent pullback might just be the beginning. Image source: Getty Images. Continue reading